Physician profile
Georgia Forrest
NPI 1366767444
$6,504.07
in general payments reported to CMS, 2019-2025
33 companies · $76.73 in 2025
The $76.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $962 · 2021: $1,124 · 2022: $1,125 · 2023: $902 · 2024: $670 · 2025: $76.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $993.27 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $558.51 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $463.39 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $428.37 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.89 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $359.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $322.62 | 2019-2023 | Dificid, Delstrigo |
| Sanofi-Aventis U.S. LLC | $221.33 | 2019-2024 | |
| Glaxosmithkline, LLC. | $193.37 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $186.69 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $179.81 | 2021-2023 | |
| Abbott Laboratories | $178.43 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $151.87 | 2022-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $142.73 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $125.54 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $50.48 | 2019-2021 | |
| Eisai INC. | $50.45 | 2020-2021 | |
| Daiichi Sankyo INC. | $44.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $42.54 | 2019 | |
| Dynavax Technologies Corporation | $39.23 | 2021-2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $33.31 | 2022 | |
| Heartflow, INC. | $24.46 | 2023 | Ffrct |
| Vanda Pharmaceuticals INC. | $18.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.06 | 2023 | Rexulti |
| Allergan, INC. | $15.16 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.63 | 2020 | |
| Exact Sciences Corporation | $14.56 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $13.97 | 2024 | Nexletol |
| Nevro Corp. | $13.62 | 2024 | Senza |
| Shire North American Group INC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgia Forrest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.